Program
lumrotatug
Also written as “CM313 injection”, “CM313” and “CM313(SC) injection”.
Its studies are mostly in Multiple Myeloma · Lupus Erythematosus, Systemic · Glomerulonephritis, IGA · Purpura, Thrombocytopenic, Idiopathic · Anemia, Aplastic, led by Keymed Biosciences.
Furthest: phase 3, since Oct 27, 202610 company-led studies, 8 open or runningNext primary completion: Mar 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keymed Biosciences | 108 open or running | phase 3since Oct 27, 2026 | Mar 24, 2021 | Mar 2027phase 2 · NCT06830395 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2021First study: phase 1 study in Multiple MyelomaFirst studyNCT04818372 · 87 enrolled · China
- Jul 7, 2022Phase 2 study in Lupus Erythematosus, SystemicNCT05465707 · 40 enrolled
- Nov 6, 2023Phase 2 study in Multiple MyelomaNCT06126237 · 120 planned
- Feb 22, 2024Phase 1 study in HealthyNCT06285227 · 51 planned · China
- Sep 10, 2024Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT06594146 · 62 enrolled · China
- Jan 15, 20253 phase 2 studiesNCT06792019, NCT06791824, NCT06791772
- Feb 11, 2025Phase 2 study in Glomerulonephritis, IGANCT06830395 · 106 planned · China
- Oct 27, 2026Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07910903 · 320 planned · China
Ahead
- Mar 2027Primary completion: phase 2 study in Glomerulonephritis, IGANCT06830395
- Nov 16, 2027Primary completion: phase 2 study in Platelet Transfusion RefractorinessNCT06792019
- Dec 2027Primary completion: phase 2 study in Anemia, AplasticNCT06791824
- May 2030Primary completion: phase 3 study in Multiple MyelomaNCT07910903
TargetBeta
CD38 →read by rule
“A monoclonal antibody directed against the human cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38), ”NCIt, by rule
Other programs on CD38
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daratumumabrule | Johnson & Johnson | phase 4 | 44 |
| isatuximabrule | Sanofi | phase 3 | 23 |
| felzartamabrule | Biogen | phase 3 | 15 |
| mezagitamabrule | Takeda | phase 3 | 11 |
| Anti-CD38 Monoclonal Antibody SCTC21Crule | Sinocelltech Group | phase 3 | 5 |
| sanritatugrule | Hangzhou Sumgen Biotech | phase 3 | 5 |
| CID-103rule | CASI Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 1 |
| Anti-CD38 Antibody-drug Conjugate ABBV-438 | AbbVie | phase 1 | 1 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07910903Multiple Myeloma · China | 3 | Not yet recruiting | May 2030 | 320 |
| NCT06830395Glomerulonephritis, IGA · China | 2 | Not yet recruiting | Mar 2027 | 106 |
| NCT06791772Lupus Erythematosus, Systemic · China | 2 | Not yet recruiting | Oct 2026 | 150 |
| NCT06792019Platelet Transfusion Refractoriness · China | 2 | Recruiting | Nov 16, 2027 | 110 |
| NCT06791824Anemia, Aplastic · China | 2 | Not yet recruiting | Dec 2027 | 125 |
| NCT06594146Purpura, Thrombocytopenic, Idiopathic · China | 2 | Active, not recruiting | Dec 30, 2025 | 62 |
| NCT06285227Healthy · China | 1 | Recruiting | Apr 30, 2025 | 51 |
| NCT06126237Multiple Myeloma | 2 | Not yet recruiting | Feb 28, 2026 | 120 |
| NCT05465707Lupus Erythematosus, Systemic | 2 | UNKNOWN | Oct 30, 2023 | 40 |
| NCT04818372Multiple Myeloma · China | 1 | UNKNOWN | Jan 2023 | 87 |
How it is read
Names in the registry
- “CM313 injection”, 5 entries
- “CM313”, 3 entries
- “CM313(SC) injection”, 3 entries
- “CM313(SC) injection-low dose”, 1 entry
- “CM313(SC) injection-high dose”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 3 studies
- Lupus Erythematosus, Systemic, 2 studies
- Glomerulonephritis, IGA, 1 study
- Purpura, Thrombocytopenic, Idiopathic, 1 study
- Anemia, Aplastic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.